September 26, 2024
Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress
September 5, 2024
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
September 4, 2024
Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
September 3, 2024
Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
September 2, 2024
Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024
August 13, 2024
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results
August 5, 2024
Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024
June 4, 2024
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 17, 2024
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
May 13, 2024
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
Displaying 1 - 10 of 26